低分子肝素治疗不稳定性心绞痛的临床观察

对67例临床诊断为不稳定性心绞痛患者，采用单盲、对照的完全随机化方法，分为低分子肝素治疗及小剂量尿激酶全治疗组。通过常规心电图和动态心电图24h缺血总负荷及30d发生心梗的例数和死亡率，比较两种治疗方法疗效和安全性。两组治疗在减少心绞痛发作和缺血总负荷方面无统计学差异，但溶栓组发生心肌梗塞（AMI）2例，发生出血5例（鼻衄2例、牙龈出血2例、便血1例）。作者认为低分子肝素治疗比小剂量尿激酶治疗有更好的安全性。

Effect of low molecular weight heparin on unstable angina]

OBJECTIVE: To evaluate the effect of low molecular weight heparin (LMWH) and verus urokinase (UK) on unstable angina (UA). METHODS: Sixty seven patients with UA were divided in two groups by a single blind, controlled, randomized method: LMWH (anti-thrombi) group and UK (thromblytic therapy) group. Total ischemia load in 24 hours ambulatory ECG, mortality and cases of acute myocardial infarction (AMI) in 30 days were employed to compare the effect and safety between two groups. RESULTS: There was no significant difference in decreasing attacks of angina pectoris and total ischemia load between two groups. The UK group had two cases of AMI and five cases of complications of bleeding (two cases of epistaxis, two cases of bleeding gums, one case of hematochezia). CONCLUSION: Antithrombin therapy is prior to thromblitic therapy, treatment of LMWH is safer than that of low dose UK in UA.